These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12654404)

  • 1. Evaluating preference effects in partially unblinded, randomized clinical trials.
    Halpern SD
    J Clin Epidemiol; 2003 Feb; 56(2):109-15. PubMed ID: 12654404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using instrumental variables to disentangle treatment and placebo effects in blinded and unblinded randomized clinical trials influenced by unmeasured confounders.
    Chaibub Neto E
    Sci Rep; 2016 Nov; 6():37154. PubMed ID: 27869205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity.
    Colagiuri B
    Clin Trials; 2010 Jun; 7(3):246-55. PubMed ID: 20421243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors.
    Hróbjartsson A; Thomsen AS; Emanuelsson F; Tendal B; Rasmussen JV; Hilden J; Boutron I; Ravaud P; Brorson S
    Int J Epidemiol; 2014 Jun; 43(3):937-48. PubMed ID: 24448109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do unblinded assessors bias muscle strength outcomes in randomized controlled trials of progressive resistance strength training in older adults?
    Liu CJ; LaValley M; Latham NK
    Am J Phys Med Rehabil; 2011 Mar; 90(3):190-6. PubMed ID: 21173683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials.
    Mathieu E; Herbert RD; McGeechan K; Herbert JJ; Barratt AL
    J Clin Epidemiol; 2014 Jun; 67(6):667-71. PubMed ID: 24767518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs.
    Kube T; Rief W
    Drug Discov Today; 2017 Apr; 22(4):729-735. PubMed ID: 27919806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective preference assessment: a method to enhance the ethics and efficiency of randomized controlled trials.
    Halpern SD
    Control Clin Trials; 2002 Jun; 23(3):274-88. PubMed ID: 12057879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based medicine: four fundamental problems with the randomized clinical trial (RCT) used to document chemical medicine.
    Ventegodt S; Andersen NJ; Brom B; Merrick J; Greydanus DE
    Int J Adolesc Med Health; 2009; 21(4):485-96. PubMed ID: 20306761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of participant preferences in unblinded randomized controlled trials.
    Floyd AH; Moyer A
    J Empir Res Hum Res Ethics; 2010 Jun; 5(2):81-93. PubMed ID: 20569152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The placebo response in clinical trials-the current state of play.
    Enck P; Klosterhalfen S
    Complement Ther Med; 2013 Apr; 21(2):98-101. PubMed ID: 23497810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are There Scenarios When the Use of Non-Placebo-Control Groups in Experimental Trial Designs Increase Expected Value to Society?
    Uyei J; Braithwaite RS
    Med Decis Making; 2016 Jan; 36(1):20-30. PubMed ID: 25977361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are randomized controlled trials controlled? Patient preferences and unblind trials.
    McPherson K; Britton AR; Wennberg JE
    J R Soc Med; 1997 Dec; 90(12):652-6. PubMed ID: 9496288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis.
    Colagiuri B; Boakes RA
    Psychopharmacology (Berl); 2010 Feb; 208(3):433-41. PubMed ID: 19997906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter?
    Poolman RW; Struijs PA; Krips R; Sierevelt IN; Marti RK; Farrokhyar F; Bhandari M
    J Bone Joint Surg Am; 2007 Mar; 89(3):550-8. PubMed ID: 17332104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinding strategies in the conduct and reporting of a randomized placebo-controlled device trial.
    Houweling AH; Shapiro S; Cohen JM; Kahn SR
    Clin Trials; 2014 Oct; 11(5):547-52. PubMed ID: 24902921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In the dark: the reporting of blinding status in randomized controlled trials.
    Montori VM; Bhandari M; Devereaux PJ; Manns BJ; Ghali WA; Guyatt GH
    J Clin Epidemiol; 2002 Aug; 55(8):787-90. PubMed ID: 12384193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of patient preference on the design and interpretation of clinical trials.
    Feine JS; Awad MA; Lund JP
    Community Dent Oral Epidemiol; 1998 Feb; 26(1):70-4. PubMed ID: 9511845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.